Journal Information
Vol. 40. Issue 3.
Pages 103-105 (March 2004)
Share
Share
Download PDF
More article options
Vol. 40. Issue 3.
Pages 103-105 (March 2004)
Full text access
Utilidad de la tomografía de emisión de positrones en el carcinoma de pulmón no microcítico
Visits
11022
M.C. Resino, A. Maldonado
Corresponding author
director@petmadrid.com

Correspondencia: Centro PET Complutense de Madrid.Manuel Bartolomé Cossío, 10. 28040 Madrid. España.
, L. García
Centro PET Complutense de Madrid. Madrid. España.
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
C. García Girón, Y. Fernández Pérez, P. Salinas Hernández, M.A. Jara Álvarez.
Cáncer de pulmón II.
Oncología clínica. Patología especial, pp. 57-80
[2.]
T.C. McLoud, P.M. Bourgouin, R.W. Greenberg.
Bronchogenic carcinoma: analysis of staging in the mediastinun with CT by correlative lymph-node mapping and sampling.
Radiology, 182 (1992), pp. 319-323
[3.]
B. Dillemans, G. Deneffe, M. Verschakelen, M. Decramer.
Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer.
Eur J Cardiothorac Surg, 8 (1994), pp. 37-42
[4.]
N.C. Gupta, G.M. Graeber, H.A. Bishop.
Comparative efficacy of PET with FDG in evaluation of small (< 1 cm), intermediate (1 to 3 cm) and larg (>3 cm) lymph node lesions.
Chest, 117 (2000), pp. 773-778
[5.]
M. Dahlbom, E.J. Hoffman, C.K. Hoh, C. Schipers, G. Rosenqvist, R.A. Hawkins, et al.
Whole-body positron emission tomography: part I, Methods and preformance characteristics.
J Nucl Med, 33 (1992), pp. 1191-1199
[6.]
R.J. Hagge, T.Z. Wong, R.E. Coleman.
Positron emission tomography: brain tumors and lung cancer.
Radiol Clin North Am, 39 (2001), pp. 871-881
[7.]
D.R. Croft, J. Trapp, K. Kernstine, P. Kirchner, B. Mullan, J. Galvin, et al.
FDG-pET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence.
Lung Cancer, 36 (2002), pp. 297-301
[8.]
J. Ortiz Mera, A. Pereira Vega, R. Ayerbe García, J. Gravalos Guzmán, J. Maldonado Pérez.
A man with lung cancer and tuberculosis: a false positive by positron emission tomography and its clinical repercussions.
Arch Bronconeumol, 38 (2002), pp. 90-92
[9.]
A. Alavi, N. Gupta, J.L. Alberini, M. Hickeson, L.E. Adam, P. Bhargava, et al.
Positron emission tomography imaging in nonmalignant thoracic disorders.
Semin Nucl Med, 32 (2002), pp. 293-321
[10.]
A.H. Khandani, S.M. Keller, M.D. Blaufox.
18Fluorodeoxyglucose positron emission tomography: false-positive lung scan.
Semin Nucl Med, 32 (2002), pp. 212-213
[11.]
K. Kubota, T. Matsuzawa, T. Fujiwara, M. Ito, J. Hatazawa, R. Iwata, et al.
Differential diagnosis of lung tumor with positron emission tomography: a prospective study.
J Nucl Med, 31 (1990), pp. 1927-1932
[12.]
J.r. Chin R, R. Ward, J.W. Keyes, R.H. Choplin, J.C. Reed, S. Wallenhaupt, et al.
Mediastinal staging of non-small cell lung cancer with PET.
Am J Respir Crit Care Med, 152 (1995), pp. 2090-2096
[13.]
P.E. Valk, T.R. Pounds, D.M. Hopkins, M.K. Haseman, G.A. Hofer, H.B. Greiss, et al.
Staging non-small cell lung cancer by wholebody positron emission tomography imaging.
Ann Thorac Surg, 60 (1995), pp. 1573-1582
[14.]
D.A. Sazon, S.M. Santiago, G.W. Soo Hoo, A. Khonsary, C. Brown, M. Mandelkern, et al.
FDG-pET in the detection and staging of lung cancer.
Am J Respir Crit Care Med, 153 (1996), pp. 417-421
[15.]
A. Guhlmann, M. Storck, J. Kotzerke, F. Moog, L. Sunder-plasmann, S.N. Reske.
Lymph node staging in non small cell lung cancer: evaluation by FDG-pET.
Thorax, 52 (1997), pp. 438-441
[16.]
J.F. Vansteenkiste, S.G. Stroobants, P.R. De Leyn, P.J. Dupont, J.A. Verschakelen, K.L. Nackaerts, et al.
Mediastinal lymph node staging with FDG-pET scan in patients with potentially operable nonsmall cell lung cancer: a prospective analysis of 50 cases. Leuven Lung cancer Group.
Chest, 112 (1997), pp. 1480-1486
[17.]
J.F. Vansteenkiste, S.G. Stroobants, P.R. De Leyn, P.J. Dupont, J. Bogaert, A. Maes, et al.
Lymph node staging in non small cell lung cancer with FDG-pET scan: a prospective study on 690 lymph node stations from 68 patients.
J Clin Oncol, 16 (1998), pp. 2142-2149
[18.]
C.A. Saunders, J.E. Dussek, M.J. O'Doherty, M.N. Maisey.
Evaluation of FDG whole body PET imaging in the staging of lung cancer.
Ann Thorac Surg, 67 (1999), pp. 790-797
[19.]
S.U. Berlangieri, A.M. Scott, S.R. Knight, G.J. Fitt, O.F. Hennessy, H.J. Tochon- Danguy, et al.
FDG-pET in non-invasive staging of nonsmall cell lung cancer.
Eur Cardiothorac Surg, 16 (1999), pp. 25-30
[20.]
E.M. Marom, H.P. McAdams, J.J. Erasmus, P.C. Goodman, D.K. Culhane, R.E. Coleman, et al.
Staging non-small cell lung cancer with whole body PET.
[21.]
T. Bury, P. Rigo.
Contribution of PET for the manegement of lung cancer.
Rev Pneumol Clin, 56 (2000), pp. 125-131
[22.]
M.A. Farrell, H.P. McAdams, J.E. Herndon, E.F. Patz.
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
[23.]
B.A. Dwamena, S.S. Sonnad, J.O. Angobaldo, R.L. Wahl.
Metastases from non-small cell lung cancer: mediastina staging in the 1990smeta- analytic comparasion of PET and CT.
[24.]
R.M. Pieterman, J.W. Van Putten, J.J. Meuzelaar, E.L. Mooyart, W. Vaalburg, G.H. Koeter, et al.
Preoperative staging of non-small cell lung cancer with positron emission tomography.
N Engl J Med, 343 (2000), pp. 254-261
[25.]
A. Fritscher-Ravens, K.H. Bohuslavizki, L. Brandt, C. Bobrowski, C. Lund, W.T. Knöfel, et al.
Mediastinal lymph node involvement in potentially resectable lung cancer. Comparison of CT, positron emission tomography and endoscopic ultrasonography with and without fine-needle aspiration.
Chest, 123 (2003), pp. 442-451
[26.]
K.H. Kernstine, K.A. Mclaughlin, Y. Menda, N.P. Rossi, D.J. Kahn, D.L. Bushnell, et al.
Can FDG-pET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?.
Ann Thorac Surg, 73 (2002), pp. 394-402
[27.]
H.J. Jeong, J.J. Min, J.M. Park, J.K. Chung, B.T. Kim, J.M. Jeong, et al.
Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer.
Nucl Med Commun, 23 (2002), pp. 865-870
[28.]
L.E. Heyneman, E.F. Patz.
PET imaging in patients with bronchioloalveolar cell carcinoma.
Lung Cancer, 38 (2002), pp. 261-266
[29.]
T. Wang, Y. Sun, N. Zhou, et al.
Fluorine-18 fluorodeoxyglucose uptake in patients with primary lung cancer.
Zhonghua Wai Ke Za Zhi, 40 (2002), pp. 437-440
[30.]
E.M. Marom, S. Sarvis, J.E. Herndon, J.r. Patz EF.
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
Radiology, 223 (2002), pp. 453-459
[31.]
N. Pandit, M. Gonen, L. Krug, A.M. Larson.
Prognostic value of [18F]FDG-pET imaging in small cell lung cancer Eur J Nucl Med, 30 (2003), pp. 78-84
[32.]
J.M. Pugsley, R.A. Schmidt, H. Vesselle.
The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography.
Cancer J, 8 (2002), pp. 222-233
[33.]
W.J. Scott, J. Shepherd, S.S. Gambhir.
Cost-effectiveness of FDGPET for staging non-small cell lung cancer: a decision analysis.
Ann Thorac Surg, 66 (1998), pp. 1876-1885
[34.]
E. Weng, L. Tran, S. Rege, A. Safa, A. Sadeghi, G. Juillard, et al.
Accuracy and clinical impact of mediastinal lymph node staging with FDG-pET imaging in potentially respectable lung cancer.
Am J Clin Oncol, 23 (2000), pp. 47-52
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?